MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) by Chen, J, Johnson, L, McKenna, K, Choi, T, Duan, J, Feng, D, Tsai, J, Garcia-Martin, N, Sompalli, K, Maute, R, Vyas, P, Majeti, R, Takimoto, C, Liu, J, Ramsingh, G, Chao, M, Volkmer, J-P, Weissman, I

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results by Sallman, D, Asch, A, Kambhampati, S, Al Malki, M, Zeidner, J, Donnellan, W, Lee, D, Vyas, P, Jeyakumar, D, Mannis, G, Tanaka, T, Chai-Ho, W, Larson, R, Whiteley, A, Marcucci, G, Komrokji, R, Garcia-Manero, G, Van Elk, J, Lin, M, Maute, R, Volkmer, J-P, Takimoto, C, Chao, M, Daver, N